Orthofix International N.V. (NASDAQ:OFIX) will issue its quarterly earnings data after the market closes on Monday, October 30th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Orthofix International N.V. has set its FY17 guidance at $1.54-1.60 EPS.

Orthofix International N.V. (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The business had revenue of $108.90 million during the quarter, compared to the consensus estimate of $102.94 million. Orthofix International N.V. had a net margin of 1.88% and a return on equity of 9.96%. The company’s revenue was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.41 earnings per share. On average, analysts expect Orthofix International N.V. to post $1.56 EPS for the current fiscal year and $1.83 EPS for the next fiscal year.

Shares of Orthofix International N.V. (NASDAQ:OFIX) traded up 0.69% on Monday, hitting $49.84. 8,242 shares of the company’s stock were exchanged. Orthofix International N.V. has a 12-month low of $32.51 and a 12-month high of $51.09. The company’s 50-day moving average price is $48.86 and its 200 day moving average price is $44.87. The stock has a market cap of $905.59 million, a price-to-earnings ratio of 116.72 and a beta of 0.20.

In other Orthofix International N.V. news, CFO Rice Doug sold 7,353 shares of Orthofix International N.V. stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $49.46, for a total transaction of $363,679.38. Following the completion of the transaction, the chief financial officer now owns 44,743 shares in the company, valued at $2,212,988.78. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Raymond Fujikawa sold 6,364 shares of Orthofix International N.V. stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $47.06, for a total transaction of $299,489.84. Following the transaction, the insider now owns 31,084 shares of the company’s stock, valued at approximately $1,462,813.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 23,406 shares of company stock valued at $1,138,531. 5.60% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Orthofix International N.V. (OFIX) Set to Announce Quarterly Earnings on Monday” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/10/23/orthofix-international-n-v-ofix-set-to-announce-quarterly-earnings-on-monday.html.

Several analysts have recently weighed in on OFIX shares. Zacks Investment Research raised shares of Orthofix International N.V. from a “sell” rating to a “hold” rating in a report on Thursday, July 6th. BidaskClub downgraded shares of Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. TheStreet raised shares of Orthofix International N.V. from a “c+” rating to a “b-” rating in a report on Tuesday, August 8th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $55.00 target price (up previously from $50.00) on shares of Orthofix International N.V. in a report on Thursday, August 10th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Orthofix International N.V. presently has an average rating of “Buy” and an average price target of $52.75.

Orthofix International N.V. Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Earnings History for Orthofix International N.V. (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with MarketBeat.com's FREE daily email newsletter.